Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer

• Published in: American journal of clinical oncology Vol. 38; no. 1; p. 28
• Main Authors: Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Akamatsu, Hiroaki, Ono, Akira, Shukuya, Takehito, Nakamura, Yukiko, Tsuya, Asuka, Murakami, Haruyasu, Takahashi, Toshiaki, Endo, Masahiro, Nakajima, Takashi, Yamamoto, Nobuyuki
• Format: Journal Article
• Language: English
• Published: United States 01.02.2015
• Subjects: Adult; Aged; Aged, 80 and over; Anthracyclines - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Carboplatin - administration & dosage; Cisplatin - administration & dosage; Cohort Studies; Etoposide - administration & dosage; Female; Humans; Induction Chemotherapy - methods; Lung Neoplasms - drug therapy; Male; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Retrospective Studies; Small Cell Lung Carcinoma - drug therapy; Time Factors; Topotecan - therapeutic use; Treatment Outcome

To evaluate the efficacy of rechallenge with current induction regimens for sensitive-relapse small cell lung cancer (SCLC) patients. We defined sensitive relapse as treatment-free interval (TFI≥90 d). Sensitive-relapse SCLC patients who received second-line chemotherapy were separated into those tr...